Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1a Study of Recibokibart (HB0034) in Healthy Adults
NCT05064345Phase 1Completed
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
- Start
- Dec 2021
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HB0034 in generalized pustular psoriasis (GPP) (8 arms), sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd. Primary endpoint: Percentage of subjects with drug related adverse events (AEs) up to 2000 hours. Started Dec 2021; status: completed.
02
Drugs
HB0034
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on NCT05064345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05064345.